Acrongenomics Signs £3.45 Million Joint Development Agreement with Molecular Vision
Complete the form below to unlock access to ALL audio articles.
Acrongenomics, Inc. and Molecular Vision, Ltd.- an Imperial Innovations spin-off company - have announced a joint collaboration intended to accelerate the development and commercialization of portable Point-of-Care (POC) diagnostic devices for personalized medical testing that will extend the tools available to the medical community.
The project outlined in the collaboration is intended to support the development of POC devices for on-the-spot diagnosis of diabetes management, STDs (Sexually Transmitted Diseases), cardiovascular diseases and substances of abuse, based on the BioLED technology developed by the Molecular Vision’s founders.
"With diagnostics and therapeutics converging in today’s healthcare market, Acrongenomics and Molecular Vision embark on a promising partnership to tackle the tough technical challenges associated with personalized medicine," said Constantine D. Poulios, president of Acrongenomics Inc.
"Through the combined strength of our teams, we will be able to deliver revolutionary POC diagnostics to market and provide sophisticated tools demanded by the global medical community."
"We look forward to working closely with Acrongenomics to develop a new generation of point-of-care diagnostic devices," said Donal Bradley co-founder of Molecular Vision Ltd.
"This collaboration enables us to progress towards our first products in a timely fashion."
